(Q46729368)

English

Bortezomib therapy in myelofibrosis: a phase II clinical trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18305559

Bortezomib therapy in myelofibrosis: a phase II clinical trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18305559

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

8

object named as

A Tefferi

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

author name string

R A Mesa

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18305559

S Verstovsek

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18305559

C Rivera

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18305559

A Pardanani

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18305559

K Hussein

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18305559

T Lasho

6

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18305559

W Wu

7

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18305559

publication date

28 February 2008

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18305559

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18305559

22

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18305559

8

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18305559

1636-1638

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18305559

https://scigraph.springernature.com/pub.10.1038/leu.2008.32

0 references

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.32

7 January 2021

based on heuristic

inferred from DOI database lookup

New and old treatment modalities in primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.32

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.32

7 January 2021

based on heuristic

inferred from DOI database lookup

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.32

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.32

7 January 2021

based on heuristic

inferred from DOI database lookup

Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.32

7 January 2021

based on heuristic

inferred from DOI database lookup

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.32

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2008.32

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18305559

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18305559

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46729368&oldid=2128521386"